Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 9/20 | 0.53 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.53 |
| ▸ | HCK | P08631 | 2/20 | 0.53 |
| ▸ | SRC | P12931 | 2/20 | 0.53 |
| ▸ | KCNJ6 | P48051 | 7/20 | 0.51 |
| ▸ | KCNJ5 | P48544 | 7/20 | 0.51 |
| ▸ | KCNJ3 | P48549 | 7/20 | 0.51 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.43 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.42 |
| ▸ | SYK | P43405 | 2/20 | 0.41 |
| ▸ | GSK3A | P49840 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4468014 | 0.97 | MAPK14 (0.51) | MAPK14MAPK12HCKSRCKCNJ6 | |
| SCHEMBL4467863 | 0.91 | MAPK14 (0.44) | MAPK14MAPK12HCKSRCKCNJ6 | |
| SCHEMBL4466421 | 0.90 | MAPK14 (0.52) | MAPK14MAPK12HCKSRCMAPK13 | |
| SCHEMBL4461487 | 0.90 | MAPK14 (0.51) | MAPK14MAPK12HCKSRCKCNJ6 | |
| SCHEMBL4466150 | 0.89 | MAPK14 (0.42) | MAPK14MAPK12HCKSRCKCNJ6 | |
| SCHEMBL13708144 | 0.88 | MAPK14 (0.57) | MAPK14MAPK12HCKSRCKCNJ6 | |
| Hydrochloric Acid SCHEMBL4465045 | 0.88 | MAPK14 (0.56) | MAPK14MAPK12HCKSRCKCNJ6 | |
| SCHEMBL4468019 | 0.83 | KCNJ6 (0.41) | MAPK14MAPK12HCKSRCKCNJ6 | |
| SCHEMBL13708149 | 0.79 | MAPK14 (0.55) | MAPK14MAPK12HCKSRCMAPK13 | |
| SCHEMBL4471507 | 0.78 | MAPK14 (0.53) | MAPK14MAPK12HCKSRCMAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10441577-B2 | Medicament for treatment of liver cancer | HELMHOLTZ ZENTRUM FUER INFEKTIONSFORSCHUNG (DE) | 2019-10-15 | — | — | US | disclosed |
| US-20150079154-A1 | MEDICAMENT FOR TREATMENT OF LIVER CANCER | HELMHOLTZ-ZENTRUM FUER INFEKTIONSFORSCHUNG GMBH (DE) | 2015-03-19 | — | — | US | disclosed |
| US-7582638-B2 | Pyrazole-isoquinoline urea derivatives as p38 kinase inhibitors | ELI LILLY AND COMPANY (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582638-B2 | Pyrazole-isoquinoline urea derivatives as p38 kinase inhibitors | ELI LILLY AND COMPANY (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582638-B2 | Pyrazole-isoquinoline urea derivatives as p38 kinase inhibitors | ELI LILLY AND COMPANY (US) | 2009-09-01 | — | — | US | disclosed |
| US-20080275056-A1 | With improved potency and greater bioavailability; 1-{1-[1-(1-Methyl-cyclopropanecarbonyl)-piperidin-4-yloxy]-isoquinolin-4-yl}-3-[5-(1-methyl-cyclopropyl)-2-p-tolyl-2H-pyrazol-3-yl]-urea; antimetastasis and antineoplastic agents, rheumatoid arthritis | ELI LILLY AND COMPANY | 2008-11-06 | — | — | US | disclosed |
| US-20080275056-A1 | With improved potency and greater bioavailability; 1-{1-[1-(1-Methyl-cyclopropanecarbonyl)-piperidin-4-yloxy]-isoquinolin-4-yl}-3-[5-(1-methyl-cyclopropyl)-2-p-tolyl-2H-pyrazol-3-yl]-urea; antimetastasis and antineoplastic agents, rheumatoid arthritis | ELI LILLY AND COMPANY | 2008-11-06 | — | — | US | disclosed |
| US-20080275056-A1 | With improved potency and greater bioavailability; 1-{1-[1-(1-Methyl-cyclopropanecarbonyl)-piperidin-4-yloxy]-isoquinolin-4-yl}-3-[5-(1-methyl-cyclopropyl)-2-p-tolyl-2H-pyrazol-3-yl]-urea; antimetastasis and antineoplastic agents, rheumatoid arthritis | ELI LILLY AND COMPANY | 2008-11-06 | — | — | US | disclosed |
| WO-2007053346-A1 | PYRAZOLE-ISOQUINOLINE UREA DERIVATIVES AS P38 KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275056-A1 | With improved potency and greater bioavailability; 1-{1-[1-(1-Methyl-cyclopropanecarbonyl)-piperidin-4-yloxy]-isoquinolin-4-yl}-3-[5-(1-methyl-cyclopropyl)-2-p-tolyl-2H-pyrazol-3-yl]-urea; antimetastasis and antineoplastic agents, rheumatoid arthritis | CNKSR1, CHUK, SLC14A1 | MAPK14 72/4885MAPK12 186/4885HCK 124/4885 |
| US-10441577-B2 | Medicament for treatment of liver cancer | PYGL, PFKL, GLS2 | MAPK14 523/4885MAPK12 538/4885HCK 1021/4885 |
| US-20150079154-A1 | MEDICAMENT FOR TREATMENT OF LIVER CANCER | PYGL, PFKL, GLS2 | MAPK14 523/4885MAPK12 538/4885HCK 1021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.